- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | PaxMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | PaxMedica, Inc.: PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 | 55 | GlobeNewswire (Europe) | TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN - PaxMedica Inc. (Nasdaq: PXMD) (the "Company"), a leading biopharmaceutical company dedicated to advancing treatments for neurological... ► Artikel lesen | |
| 17.04. | PaxMedica rises on Malawi's request for access to sleeping sickness drug | 4 | Reuters | ||
| 16.04. | PaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness | 251 | GlobeNewswire (Europe) | Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously... ► Artikel lesen | |
| 12.04. | Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies | 4 | Benzinga.com | ||
| 12.04. | Why is PaxMedica (PXMD) stock surging today? | 1 | iNVEZZ.com | ||
| 12.04. | Why Is PaxMedica (PXMD) Stock Up 93% Today? | 8 | InvestorPlace | ||
| 11.04. | PaxMedica shares soar 125% post-market on drug update | 4 | Seeking Alpha | ||
| 11.04. | PaxMedica, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.04. | PaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission | 236 | GlobeNewswire (Europe) | TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN - PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced... ► Artikel lesen | |
| 22.03. | PaxMedica, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.03. | PaxMedica, Inc.: PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments | 2 | GlobeNewswire (USA) | ||
| 13.03. | PaxMedica, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | PaxMedica, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 29.01. | PaxMedica, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.01. | PaxMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.12.23 | PaxMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12.23 | PaxMedica shares progress on ASD treatment, including FDA meeting and funding | 6 | Investing.com | ||
| 06.12.23 | PaxMedica, Inc.: PaxMedica Releases Fireside Chat Video with CEO Howard Weisman | 459 | ACCESSWIRE | TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Fireside... ► Artikel lesen | |
| 04.12.23 | PaxMedica's suramin treatment for ASD gains spotlight in analyst report | 2 | Investing.com |
Seite:
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| JANUX THERAPEUTICS | 56,08 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SPRINGWORKS THERAPEUTICS | 46,450 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| IMMUNOVANT | 27,490 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
| CABALETTA BIO | 10,480 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,380 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| NUVALENT | 67,95 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| ARCELLX | 51,11 | 0,00 % | Should You Be Bullish on Arcellx (ACLX)? | ||
| CULLINAN THERAPEUTICS | 27,120 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,200 | 0,00 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| BEAM THERAPEUTICS | 22,050 | +3,13 % | Expert Ratings For Beam Therapeutics | ||
| ARVINAS | 31,900 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 34,660 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,460 | +2,95 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 24,700 | +1,40 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 16,480 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen |
PAXMEDICA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,741 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
